^
Association details:
Biomarker:No biomarker
Cancer:Mantle Cell Lymphoma
Drug:Imbruvica (ibrutinib) (BTK inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Published date:
10/21/2014
Excerpt:
Imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Mantle cell lymphoma: Other recommended regimens...Ibrutinib TRIANGLE regimen: Alternating RCHOP + covalent BTKig/RDHA (rituximab, dexamethasone, cytarabine) + platinum (carboplatin, cisplatin, or oxaliplatin) (category 2A for ibrutinib; category 2B for acalabrutinib or zanubrutinib)
Secondary therapy:
R-CHOP
Evidence Level:
Sensitive: B - Late Trials
Source:
Title:

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

Published date:
12/07/2015
Excerpt:
This randomised, open-label, multicentre, phase 3 clinical trial enrolled patients with relapsed or refractory mantle-cell lymphoma….Primary efficacy analysis showed significant improvement in progression-free survival (p<0·0001) for patients treated with ibrutinib versus temsirolimus (hazard ratio 0·43 [95% CI 0·32–0·58]...
DOI:
10.1016/S0140-6736(15)00667-4